Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0/II Study of Ceritinib (LDK378) in Preoperative Glioblastoma Multiforme (GBM) and CNS Metastasis Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration

NCT02605746 is registered in ClinicalTrials.gov with St. Joseph's Hospital and Medical Center, Phoenix as lead sponsor.

NCT NCT02605746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02605746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0/II Study of Ceritinib (LDK378) in Preoperative Glioblastoma Multiforme (GBM) and CNS Metastasis Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Phase
Phase 1
Overall status
Completed
Start date
February 17, 2016
Completion date
July 12, 2019
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, glioblastoma